Literature DB >> 1541035

Insulin resistance and cardiovascular drugs.

H Lithell1.   

Abstract

Under certain circumstances the effect of insulin to promote glucose uptake in peripheral tissues is reduced because of a resistance to insulin action. This insulin resistance and the resulting hyperinsulinaemia are now recognised as common background factors that may be responsible for hypertension, hyperlipidaemia, decreased thrombolysis and also impaired glucose tolerance and diabetes. Hyperinsulinaemia has also been identified as an independent risk factor for coronary heart disease and promotes smooth muscle cell growth and plaque formation. A series of studies have now demonstrated that treatment with selective beta-blockers as well as thiazide diuretics impair insulin sensitivity by 15-30% and causes a compensatory increase in insulin concentrations. Furthermore, lipoprotein concentrations are affected in an unfavourable way. This is in contrast to the drugs belonging to ACE-inhibitors, calcium-channel blockers and alpha 1-blocker classes that are either neutral or may have the opposite effects in these respects.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1541035     DOI: 10.3109/10641969209036178

Source DB:  PubMed          Journal:  Clin Exp Hypertens A        ISSN: 0730-0077


  3 in total

Review 1.  Metabolic effects of antihypertensive agents: role of sympathoadrenal and renin-angiotensin systems.

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-06-17       Impact factor: 3.000

2.  Verapamil SR and trandolapril combination therapy in hypertension--a clinical trial of factorial design. German Hypertension Study Group.

Authors:  J Scholze; P Zilles; D Compagnone
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 3.  The inter-relationship between insulin resistance and hypertension.

Authors:  A Salvetti; G Brogi; V Di Legge; G P Bernini
Journal:  Drugs       Date:  1993       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.